Thyroid storm induced by combined nivolumab and ipilimumab immunotherapy in advanced non-small cell lung cancer

被引:6
|
作者
Kataoka, Shunichi [1 ]
Matsuno, Kei [1 ]
Sugano, Koji [1 ]
Takahashi, Kazuhisa [2 ]
机构
[1] Juntendo Tokyo Koto Geriatr Med Ctr, Div Resp Med, Koto Ku, Tokyo, Japan
[2] Juntendo Univ, Sch Med, Grad Sch Med, Bunkyo Ku, Tokyo, Japan
关键词
Endocrine system; Thyroid disease; Lung cancer (oncology); ASSOCIATION; GUIDELINES; MANAGEMENT;
D O I
10.1136/bcr-2022-250696
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thyroid storm is a rare and life-threatening condition associated with excess thyroid hormones. Early detection of thyroid storm is the key to decreasing the morbidity and mortality associated with this condition. We present a rare case of thyroid storm induced by combination therapy with nivolumab and ipilimumab in a patient with advanced non-small cell lung cancer (NSCLC). Because of prominent hyperthyroidism with gastrointestinal symptoms and signs of heart failure, the patient was diagnosed with thyroid storm 3 weeks after initiating this combination immunotherapy. The patient had no history of thyroid disease but was positive for antithyroid antibodies. This case report suggests that thyroid function and symptoms of suspected thyroid storm should be evaluated routinely within 3 weeks from the initiation of therapy when combination therapy is administered in patients with NSCLC positive for antithyroid antibodies.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
    Wu, Xinyu
    Chau, Yi Fung
    Bai, Hua
    Zhuang, Xiaofei
    Wang, Jie
    Duan, Jianchun
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [42] Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer
    Yasuda, Yuichiro
    Urata, Yoshiko
    Tohnai, Rie
    Ito, Shoichi
    Kawa, Yoshitaka
    Kono, Yuko
    Hattori, Yoshihiro
    Tsuda, Masahiro
    Sakuma, Toshiko
    Negoro, Shunichi
    Satouchi, Miyako
    INTERNAL MEDICINE, 2018, 57 (09) : 1269 - 1272
  • [43] Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer
    Chang, Jeremy
    Tran, Jeffrey
    Kamel, Dina
    Basu, Arnab
    BMJ CASE REPORTS, 2019, 12 (03)
  • [44] Multimodal treatment of oligometastatic non-small cell lung cancer
    Graca, Luis Lourenco
    Pego, Alice
    Lareiro, Susana
    Pancas, Rita
    BMJ CASE REPORTS, 2023, 16 (12)
  • [45] Nivolumab-induced thyroid dysfunction in patients with lung cancer
    Ramos-Levi, Ana M.
    Rogado, Jacobo
    Miguel Sanchez-Torres, Jose
    Colomer, Ramon
    Marazuela, Monica
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2019, 66 (01): : 26 - 34
  • [46] Mobocertinib in non-small cell lung cancer
    Liu, Shengwu
    Lowder, Kristen E.
    DRUGS OF TODAY, 2022, 58 (11) : 523 - 530
  • [47] Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer
    Kishida, Yukiko
    Hirose, Takashi
    Shirai, Takao
    Sugiyama, Tomohide
    Kusumoto, Soujiro
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Adachi, Mitsuru
    Nakamura, Akihiro
    ONCOLOGY LETTERS, 2011, 2 (05) : 949 - 955
  • [48] A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
    Hurkmans, Daan P.
    Basak, Edwin A.
    van Dijk, Tanja
    Mercieca, Darlene
    Schreurs, Marco W. J.
    Wijkhuijs, Annemarie J. M.
    Bins, Sander
    Oomen-de Hoop, Esther
    Debets, Reno
    Joerger, Markus
    Odink, Arlette
    van der Veldt, Astrid A. M.
    van der Leest, Cor H.
    Aerts, Joachim G. J., V
    Mathijssen, Ron H. J.
    Koolen, Stijn L. W.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study
    Nie, Wei
    Lu, Jun
    Qian, Jie
    Wang, Shu-Yuan
    Cheng, Lei
    Zheng, Liang
    Tao, Guang-Yu
    Zhang, Xue-Yan
    Chu, Tian-Qing
    Han, Bao-Hui
    Zhong, Hua
    BMC MEDICINE, 2024, 22 (01):
  • [50] Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review
    Dudzinska, Marta
    Szczyrek, Michal
    Wojas-Krawczyk, Kamila
    Swirska, Joanna
    Chmielewska, Izabela
    Zwolak, Agnieszka
    CANCERS, 2020, 12 (08) : 1 - 21